Benzinga | Nov 19, 2021 09:03AM EST

Context Therapeutics Reports Will Present Clinical Data On ONA-XR In Breast Cancer At San Antonio Breast Cancer Symposium Dec. 8, 9

Context Therapeutics Inc. (NASDAQ:CNTX), a women's oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers, today announced clinical data on onapristone extended release (ONA-XR) will be presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place virtually and in San Antonio, Texas, from December 7-10, 2021.

"We are pleased that ONA-XR data from multiple stages of breast cancer will be presented at SABCS including the first clinical data from the ONAWA trial, sponsored by the Spanish cancer research group SOLTI, of ONA-XR in early-stage breast cancer and updates from two ongoing clinical trials of ONA-XR in metastatic breast cancer. We look forward to connecting with the oncology community at SABCS, to discuss advancements in breast cancer and further highlight the potential of ONA-XR to make a meaningful impact in the lives of people living with breast cancer," said Martin Lehr, CEO of Context Therapeutics.

Details on the presentations are as follows:

Title: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC)

Abstract: 511

Session: Poster Session 1, Prognostic and Predictive Factors: Predictive Biomarkers for Endocrine Therapies

Date / time: Wednesday, December 8, 2021, 8-9:30 a.m. ET / 7-8:30 a.m. CT

Presenter: Meritxell Bellet, M.D., Ph.D., SOLTI Breast Cancer Research Group, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona

Title: The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2- metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors

Abstract: 379

Session: Ongoing Trials Poster Sessions 2, Targeted therapy - antiprogestin onapristone

Date / time: Thursday, December 9, 2021, 6-7:30 p.m. ET / 5-6:30 p.m. CT

Presenter: Sailaja Kamaraju, M.D., Medical College of Wisconsin, Milwaukee, Wis., and Kari Wisinski, M.D., University of Wisconsin - Madison

Title: Circulating tumor DNA-guided adaptive therapy escalation in ER+ MBC: A phase 1b study with letrozole, palbociclib and onapristone ER

Abstract: 1538

Session: Ongoing Trials Poster Session 2, Patient management - circulating tumor guided adaptive therapy

Date / time: Thursday, December 9, 2021, 6-7:30 p.m. ET / 5-6:30 p.m. CT

Presenter: Joshua Drago, M.D., Pedram Razavi, M.D., Ph.D., and Komal Jhaveri, M.D., Memorial Sloan Kettering Cancer Center

Details on the presentations listed above are also available on the 2021 SABCS website: https://www.sabcs.org/Program/Schedule-at-a-Glance.